Literature DB >> 14515089

Diagnosis and management of esthesioneuroblastoma.

Patrick J Bradley1, Nick S Jones, Iain Robertson.   

Abstract

Esthesioneuroblastoma is an uncommon malignant neoplasm of the nasal vault that in the past was considered benign or low-grade malignant. Surgical approaches in the main were transnasal, with a high recurrence rate and ultimate patient death. With the modern imaging of CT and MRI, should the patient be willing and fit enough, esthesioneuroblastoma currently should be approached using a craniofacial resection. Large tumors should be considered for preoperative chemotherapy and postoperative radiotherapy. Local tumor recurrence is not uncommon and is generally related to the attention to local anatomic dissection. Neck metastases, when they present, should be excised using a modified neck dissection. Distant metastases may present at any time during the course of the disease, generally within 36 months, and may respond to local radiotherapy or systemic chemotherapy. Five-year survival currently appears to be optimized by surgery followed by postoperative radiotherapy and is approximately 65%.

Entities:  

Mesh:

Year:  2003        PMID: 14515089     DOI: 10.1097/00020840-200304000-00009

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  34 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

Review 2.  Intracavitary chemotherapy (Gliadel) for recurrent esthesioneuroblastoma: case report and review of the literature.

Authors:  Michael C Park; Charles E Weaver; John E Donahue; Prakash Sampath
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

Review 3.  Retropharyngeal lymph node metastasis from olfactory neuroblastoma: A report of two cases.

Authors:  Hyun Jik Kim; Jinna Kim; Joo-Heon Yoon
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-12       Impact factor: 2.503

4.  Esthesioneuroblastoma metastatic to the trachea.

Authors:  F Mattavelli; N Pizzi; E Pennacchioli; S Radaelli; G Calarco; P Quattrone; L Patelli; P Spinelli
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-06       Impact factor: 2.124

Review 5.  Imaging Characteristics of Olfactory Neuroblastoma (Esthesioneuroblastoma).

Authors:  Arthur B Dublin; Matthew Bobinski
Journal:  J Neurol Surg B Skull Base       Date:  2015-09-14

6.  Esthesioneuroblastomas: Reservations and Recommendations.

Authors:  Rajesh Nair; Bhavna Nayal; Vinod Kumar; Padmapriya Jaiprakash
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 7.  Olfactory Neuroblastoma.

Authors:  Ahmed S Abdelmeguid
Journal:  Curr Oncol Rep       Date:  2018-02-07       Impact factor: 5.075

8.  Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.

Authors:  Ronald Koschny; Heidrun Holland; Jaromir Sykora; Hande Erdal; Wolfgang Krupp; Manfred Bauer; Ulrike Bockmuehl; Peter Ahnert; Jürgen Meixensberger; Wolfgang Stremmel; Henning Walczak; Tom M Ganten
Journal:  J Neurooncol       Date:  2009-09-20       Impact factor: 4.130

9.  Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine.

Authors:  Salvatore Turano; Candida Mastroianni; Caterina Manfredi; Rosalbino Biamonte; Silvia Ceniti; Virginia Liguori; Rosanna De Simone; Serafino Conforti; Aldo Filice; Antonio Rovito; Caterina Viscomi; Giuseppe Patitucci; Salvatore Palazzo
Journal:  J Neurooncol       Date:  2009-11-19       Impact factor: 4.130

10.  A study of tumours giving rise to unilateral proptosis.

Authors:  Prashant Keche; A Z Nitnaware; Manish Mair; P Sakhare; Satish Satpute
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.